Welcome to the New Year’s edition of Weekend Wonderings. I hope that everyone brought in the New Year in a safe and enjoyable manner. And, didn’t overindulge. Too much.
Mali, Eric and Joe spent last week going up and down the hallway here at tBBC World Headquarters reminding us to empty out our Inboxes to get ready for the new year. Let me dust things off to see what I can find..
Here we go; something from The James, something from Cleveland Clinic and a miscellaneous brain-dump in the Commentary. We wrap it up with some help from Bob Seger.
The James/Wexner, Cleveland Clinic
Here is some research news from The James.
“A new study led by researchers at the (OSUCCC – James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.In clinical trials, ibrutinib has often shown exceptional activity in people with chronic lymphocytic leukemia (CLL). The agent targets a molecule called Bruton’s tyrosine kinase (BTK). It permanently incapacitates the molecule, and this stops the transmission of an important signal that promotes cell growth and proliferation.But ibrutinib also inhibits other molecules in CLL cells. Like BTK, these molecules are proteins called kinases, and they might be important for CLL-cell survival, the researchers say.”
This is a pretty big deal. Now the research is targeting specific, and related molecules in cancer treatment. This type of success will lead to “peeling the onion” with further research, and provide some guidance to development and use of this type of treatment.